BRIEF-Organogenesis Q4 Revenue USD 126.7 Million

Reuters

02-28

BRIEF-Organogenesis Q4 Revenue USD 126.7 Million

Feb 27 (Reuters) - Organogenesis Q4 operating income USD 10.2 million.

Q4 adjusted net income USD 8.8 million
Q4 net income USD 7.7 million
Q4 adjusted EBITDA USD 18.2 million
outlook FY EBITDA USD 27-66.6 million
outlook FY adjusted EBITDA USD 43.6-83.2 million

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2514133094"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2514133094\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2514133094?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-28 05:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2514133094","market":"us","top_or_hot":-1,"title":"BRIEF-Organogenesis Q4 Revenue USD 126.7 Million","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\">\n<head>\n<meta/>\n<title>BRIEF-Organogenesis Q4 Revenue USD 126.7 Million</title>\n</head>\n<body>\n<p>Feb 27 (Reuters) - Organogenesis Q4 operating income USD 10.2 million.</p>\n<ul>\n<li>Q4 adjusted net income USD 8.8 million</li>\n<li>Q4 net income USD 7.7 million</li>\n<li>Q4 adjusted EBITDA USD 18.2 million</li>\n<li>outlook FY EBITDA USD 27-66.6 million</li>\n<li>outlook FY adjusted EBITDA USD 43.6-83.2 million</li>\n</ul>\n</body>\n</html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Organogenesis Q4 Revenue USD 126.7 Million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Organogenesis Q4 Revenue USD 126.7 Million\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-02-28 05:05</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\">\n<head>\n<meta/>\n<title>BRIEF-Organogenesis Q4 Revenue USD 126.7 Million</title>\n</head>\n<body>\n<p>Feb 27 (Reuters) - Organogenesis Q4 operating income USD 10.2 million.</p>\n<ul>\n<li>Q4 adjusted net income USD 8.8 million</li>\n<li>Q4 net income USD 7.7 million</li>\n<li>Q4 adjusted EBITDA USD 18.2 million</li>\n<li>outlook FY EBITDA USD 27-66.6 million</li>\n<li>outlook FY adjusted EBITDA USD 43.6-83.2 million</li>\n</ul>\n</body>\n</html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ORGO","symbol_name":"Organogenesis Holdings Inc","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250227:nPLX89D309:1","article_id":"2514133094","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2514133094","pubTimestamp":1740690346,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Feb 27  - Organogenesis Q4 operating income USD 10.2 million.","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"ORGO":"Organogenesis Holdings Inc"},"translate_title":"简介-Organogenesis第四季度收入1.267亿美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ORGO":0.9},"content_text":"BRIEF-Organogenesis Q4 Revenue USD 126.7 Million\n\n\nFeb 27 (Reuters) - Organogenesis Q4 operating income USD 10.2 million.\n\nQ4 adjusted net income USD 8.8 million\nQ4 net income USD 7.7 million\nQ4 adjusted EBITDA USD 18.2 million\noutlook FY EBITDA USD 27-66.6 million\noutlook FY adjusted EBITDA USD 43.6-83.2 million","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0}}}